TY -的T1 Mepolizumab有效性和鉴别ification of super-responders in severe asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02420-2019 VL - 55 IS - 5 SP - 1902420 AU - Harvey, Erin S. AU - Langton, David AU - Katelaris, Constance AU - Stevens, Sean AU - Farah, Claude S. AU - Gillman, Andrew AU - Harrington, John AU - Hew, Mark AU - Kritikos, Vicky AU - Radhakrishna, Naghmeh AU - Bardin, Philip AU - Peters, Matthew AU - Reynolds, Paul N. AU - Upham, John W. AU - Baraket, Melissa AU - Bowler, Simon AU - Bowden, Jeffrey AU - Chien, Jimmy AU - Chung, Li Ping AU - Grainge, Christopher AU - Jenkins, Christine AU - Katsoulotos, Gregory P. AU - Lee, Joy AU - McDonald, Vanessa M. AU - Reddel, Helen K. AU - Rimmer, Janet AU - Wark, Peter A.B. AU - Gibson, Peter G. Y1 - 2020/05/01 UR - //www.qdcxjkg.com/content/55/5/1902420.abstract N2 - Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population.The Australian Mepolizumab Registry (AMR) was established with an aim to assess the use, effectiveness and safety of mepolizumab for severe eosinophilic asthma in Australia.Patients (n=309) with severe eosinophilic asthma (median age 60 years, 58% female) commenced mepolizumab. They had poor symptom control (median Asthma Control Questionnaire (ACQ)-5 score of 3.4), frequent exacerbations (median three courses of oral corticosteroids (OCS) in the previous 12 months), and 47% required daily OCS. Median baseline peripheral blood eosinophil level was 590 cells·µL−1. Comorbidities were common: allergic rhinitis 63%, gastro-oesophageal reflux disease 52%, obesity 46%, nasal polyps 34%.Mepolizumab treatment reduced exacerbations requiring OCS compared with the previous year (annualised rate ratio 0.34 (95% CI 0.29–0.41); p<0.001) and hospitalisations (rate ratio 0.46 (95% CI 0.33–0.63); p<0.001). Treatment improved symptom control (median ACQ-5 reduced by 2.0 at 6 months), quality of life and lung function. Higher blood eosinophil levels (p=0.003) and later age of asthma onset (p=0.028) predicted a better ACQ-5 response to mepolizumab, whilst being male (p=0.031) or having body mass index ≥30 (p=0.043) predicted a lesser response. Super-responders (upper 25% of ACQ-5 responders, n=61, 24%) had a higher T2 disease burden and fewer comorbidities at baseline.Mepolizumab therapy effectively reduces the significant and long-standing disease burden faced by patients with severe eosinophilic asthma in a real-world setting.In clinical practice, mepolizumab reduces the burden of severe eosinophilic asthma by reducing severe exacerbations and improving asthma control, quality of life and lung function. Super-responders have a T2 phenotype and few comorbidities. http://bit.ly/2UIio4x ER -